CatalYm today announced the presentation of the first preclinical data demonstrating that the company's clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug ...

Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation ...

CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations ...